News | September 02, 2023
USFDA delegation visits Amneal Pharmaceutical facility in Matoda
Amneal’s site in Matoda is one of the company’s 12 pharmaceutical manufacturing facilities
Amneal’s site in Matoda is one of the company’s 12 pharmaceutical manufacturing facilities
Sets price band at ?695 to ?735 per Equity Share
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Meningitis still affects more than 2.5 million people globally each year
Pirfenidone Capsules had estimated annual sales of USD 95 million in the US
Prasugrel tablets are indicated to reduce the rate of thrombotic CV events
The approval bolsters the company's Mycophenolate Mofetil portfolio
Propranolol LA is a generic equivalent of Inderal LA
Subscribe To Our Newsletter & Stay Updated
